[Clinical evaluation of broncho-vaxom efficiency].
Broncho-vaxom was administered to 40 patients with recurrent respiratory infections, allergic-infectious bronchial asthma and chronic bronchitis. Broncho-vaxom was administered in the dose of one capsule for the first month, and 1 capsule for 10 days in the third, fourth, and fifth month. A favourable clinical effect has been achieved in over 50% of the treated patients manifested by the decrease in the number and severity of respiratory infections and reductions in antibiotics use. These results confirm clinical efficiency of this vaccine.
Moniuszko
T
T
Kliniki Alergologii AM, Białymstoku.
Rogalewska
A
A
Chyrek-Borowska
S
S
D000276:Adjuvants, Immunologic / Q000627:therapeutic use*; D000328:Adult; D001249:Asthma / Q000188:drug therapy*; D001419:Bacteria; D001991:Bronchitis / Q000188:drug therapy; D002457:Cell Extracts; D002908:Chronic Disease; D004334:Drug Administration Schedule; D005069:Evaluation Studies as Topic; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D012141:Respiratory Tract Infections / Q000188:drug therapy*; D016896:Treatment Outcome; D000095983:Bacterial Lysates
D000276:Adjuvants, Immunologic; D002457:Cell Extracts; C030259:Broncho-Vaxom; D000095983:Bacterial Lysates
Kliniczna ocena skuteczności preparatu Broncho-Vaxom.